Slovenian pharmaceutical company Krka reported 8% sales growth in the first quarter, driven by strong regional performance and prescription drug sales.
Eastern Europe led regional growth with a 13% increase, mainly due to Russia. Prescription drug sales rose 10%, while over-the-counter products fell 8%.
EBITDA climbed 20% year-over-year to €175.7 million, with margin expanding to 31.0% (up 310 bps). Gross margin improved to 60.4% (up 210 bps), supported by cost discipline.
Net profit fell to €121 million, down 21% from last year, due to foreign exchange base effects from a prior-year Russian ruble gain.
The company reiterated its 2026 guidance, maintaining plans for capital expenditure and portfolio expansion.
Krka conducted €13.6 million in share buybacks during Q1 2026.
